Skip to content
2000
Volume 32, Issue 8
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Introduction

Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons within the substantia nigra, leading to progressive motor dysfunction. There are still limited disease-modifying options that counteract the process of disease progression. This study aimed to evaluate the neuroprotective effects of thymol, both in its free form and when loaded onto selenium nanoparticles (SeNPs), in a 6-hydroxydopamine (6-OHDA)-induced PD model using SH-SY5Y cells.

Methods

SeNPs were synthesized using a chemical reduction method with ascorbic acid, achieving a 68% entrapment efficiency for thymol. FTIR analysis suggested an interaction between thymol and selenium, which was confirmed by EDX analysis. Nano-Se-thymol particles were observed to be spherical, with a mean size of 135.7 nm and a negative surface charge.

Results

Nano-Se-thymol exhibited low toxicity in normal fibroblast cells and demonstrated greater neuroprotective effects against 6-OHDA-induced cytotoxicity compared to thymol. Nano-Se-thymol significantly reduced ROS generation and increased cell viability compared to 6-OHDA. Furthermore, Nano-Se-thymol decreased the expression of NF-κB inflammatory markers and caspase-3 apoptotic proteins, which were elevated by 6-OHDA, compared to thymol alone.

Discussion

Nano-Se-Thymol significantly attenuates 6-OHDA-induced cytotoxicity in an established model of PD. The neuroprotective efficacy of Nano-Se-Thymol is attributed to its enhanced antioxidant capacity, as evidenced by a significant reduction in ROS levels, along with its ability to inhibit apoptosis and modulate cell cycle progression.

Conclusion

Nano-Se-thymol is a potential disease-modifying agent for the treatment of PD; however, further studies and long-term safety assessments are essential to confirm these benefits and understand the underlying mechanisms.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128380006250630103711
2025-07-16
2026-03-02

  • From This Site

    /content/journals/cpd/10.2174/0113816128380006250630103711
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FeiginV.L. AbajobirA.A. AbateK.H. Global, regional, and national burden of neurological disorders during 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015.Lancet Neurol.2017161187789710.1016/S1474‑4422(17)30299‑5 28931491
     [Google Scholar]
  2. DorseyE.R. ElbazA. NicholsE. Global, regional, and national burden of Parkinson’s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol.2018171193995310.1016/S1474‑4422(18)30295‑3 30287051
     [Google Scholar]
  3. OuZ. PanJ. TangS. Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019.Front. Public Health2021977684710.3389/fpubh.2021.776847 34950630
     [Google Scholar]
  4. SurmeierD.J. Determinants of dopaminergic neuron loss in Parkinson’s disease.FEBS J.2018285193657366810.1111/febs.14607 30028088
     [Google Scholar]
  5. ChenR. BerardelliA. BhattacharyaA. Clinical neurophysiology of Parkinson’s disease and parkinsonism.Clin. Neurophysiol. Pract.2022720122710.1016/j.cnp.2022.06.002 35899019
     [Google Scholar]
  6. GrimesD. FitzpatrickM. GordonJ. Canadian guideline for Parkinson disease.CMAJ201919136E989E100410.1503/cmaj.181504 31501181
     [Google Scholar]
  7. ArmstrongM.J. OkunM.S. Diagnosis and treatment of Parkinson disease: A review.JAMA2020323654856010.1001/jama.2019.22360 32044947
     [Google Scholar]
  8. CerriS. BlandiniF. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease.Expert Opin. Pharmacother.202021182279229110.1080/14656566.2020.1805432 32804544
     [Google Scholar]
  9. VijiaratnamN. SimuniT. BandmannO. MorrisH.R. FoltynieT. Progress towards therapies for disease modification in Parkinson’s disease.Lancet Neurol.202120755957210.1016/S1474‑4422(21)00061‑2 34146514
     [Google Scholar]
  10. RibbaB. SimuniT. MarekK. Modeling of Parkinson’s disease progression and implications for detection of disease modification in treatment trials.J. Parkinsons Dis.20241461225123510.3233/JPD‑230446 39058452
     [Google Scholar]
  11. VerschuurC.V.M. SuwijnS.R. BoelJ.A. Randomized delayed-start trial of levodopa in Parkinson’s disease.N. Engl. J. Med.2019380431532410.1056/NEJMoa1809983 30673543
     [Google Scholar]
  12. DawsonVL DawsonTM Promising disease-modifying therapies for Parkinson’s disease.Sci Transl Med201911520eaba165910.1126/scitranslmed.aba165931776289
     [Google Scholar]
  13. MiaoZ. BaiJ. ShenL. SinglaR.K. The combination of tradition and future: Data-driven natural-product-based treatments for Parkinson’s disease.Evid. Based Complement. Alternat. Med.202120211810.1155/2021/9990020 34335855
     [Google Scholar]
  14. KowalczykA. PrzychodnaM. SopataS. BodalskaA. FeckaI. Thymol and thyme essential oil—new insights into selected therapeutic applications.Molecules20202518412510.3390/molecules25184125 32917001
     [Google Scholar]
  15. Gholami-AhangaranM. Ahmadi-DastgerdiA. AziziS. BasiratpourA. ZokaeiM. DerakhshanM. Thymol and carvacrol supplementation in poultry health and performance.Vet. Med. Sci.20228126728810.1002/vms3.663 34761555
     [Google Scholar]
  16. TimalsinaB. HaqueM.N. ChoiH.J. DashR. MoonI.S. Thymol in Trachyspermum ammi seed extract exhibits neuroprotection, learning, and memory enhancement in scopolamine‐induced Alzheimer’s disease mouse model.Phytother. Res.20233772811282610.1002/ptr.7777 36808768
     [Google Scholar]
  17. BatoolA. SaleemS. NaqviF. HasanK.A. NaqviF. HaiderS. Thymol mitigates cadmium-induced behavioral and cognitive deficits by up-regulating hippocampal BDNF levels in rats.Pak. J. Pharm. Sci.2022352671678 35668569
     [Google Scholar]
  18. AziziZ. SalimiM. AmanzadehA. MajelssiN. NaghdiN. Carvacrol and thymol attenuate cytotoxicity induced by amyloid β25-35 via activating protein kinase c and inhibiting oxidative stress in PC12 cells.Iran. Biomed. J.202024424325010.29252/ibj.24.4.243 32306722
     [Google Scholar]
  19. OgalyH.A. Abdel-RahmanR.F. MohamedM.A.E. Ahmed-FaridO.A. KhattabM.S. Abd-ElsalamR.M. Thymol ameliorated neurotoxicity and cognitive deterioration in a thioacetamide-induced hepatic encephalopathy rat model; Involvement of the BDNF/CREB signaling pathway.Food Funct.202213116180619410.1039/D1FO04292K 35583008
     [Google Scholar]
  20. PengX. ZhangX. SharmaG. DaiC. Thymol as a potential neuroprotective agent: Mechanisms, efficacy, and future prospects.J. Agric. Food Chem.202472136803681410.1021/acs.jafc.3c06461 38507708
     [Google Scholar]
  21. LiangD. LiF. FuY. Thymol inhibits LPS-stimulated inflammatory response via down-regulation of NF-κB and MAPK signaling pathways in mouse mammary epithelial cells.Inflammation201437121422210.1007/s10753‑013‑9732‑x 24057926
     [Google Scholar]
  22. ZhouE. FuY. WeiZ. YuY. ZhangX. YangZ. Thymol attenuates allergic airway inflammation in ovalbumin (OVA)-induced mouse asthma.Fitoterapia20149613113710.1016/j.fitote.2014.04.016 24785965
     [Google Scholar]
  23. El-HadiA.A. AhmedH.M. ZakiR.A. MohsenA.M. Enhanced enzymatic activity of Strepromyces griseoplanus L-asparginase cia its incorporation in an oil-based nanocarrier.Int J Appl Pharm2020202020321010.22159/ijap.2020v12i5.38360
     [Google Scholar]
  24. MohsenA.M. NagyY.I. ShehabeldineA.M. OkbaM.M. Thymol-Loaded Eudragit RS30D cationic nanoparticles-based hydrogels for topical application in wounds: In vitro and in vivo evaluation.Pharmaceutics20221511910.3390/pharmaceutics15010019 36678648
     [Google Scholar]
  25. LiA. TysonJ. PatelS. Emerging nanotechnology for treatment of Alzheimer’s and Parkinson’s disease.Front. Bioeng. Biotechnol.2021967259410.3389/fbioe.2021.672594 34113606
     [Google Scholar]
  26. AbousamraM.M. MohsenA.M. Solid lipid nanoparticles and nanostructured lipid carriers of tolnaftate: Design, optimization and in-vitro evaluation.Int. J. Pharm. Pharm. Sci.201681380385
     [Google Scholar]
  27. EinafsharE. Haghighi AslA. RamezaniM. HashemniaA. MalekzadehA. Synthesis and characterization of multifunctional graphene oxide with gamma-cyclodextrin and SPION as new nanocarriers for drug delivery.Appl Chem Today201914513550
     [Google Scholar]
  28. MikhailovaE.O. Selenium nanoparticles: Green synthesis and biomedical application.Molecules20232824812510.3390/molecules28248125 38138613
     [Google Scholar]
  29. HosnedlovaB. KepinskaM. SkalickovaS. Nano-selenium and its nanomedicine applications: A critical review.Int. J. Nanomedicine2018132107212810.2147/IJN.S157541 29692609
     [Google Scholar]
  30. KalčecN. PeranićN. MamićI. Selenium nanoparticles as potential drug-delivery systems for the treatment of Parkinson’s disease.ACS Appl. Nano Mater.2023619175811759210.1021/acsanm.3c02749
     [Google Scholar]
  31. UmapathyS. PanI. IssacP.K. Selenium nanoparticles as neuroprotective agents: Insights into molecular mechanisms for Parkinson’s disease treatment.Mol. Neurobiol.202412810.1007/s12035‑024‑04253‑x 38837103
     [Google Scholar]
  32. SalaramoliS. AmiriH. JoshaghaniH.R. HosseiniM. HashemyS.I. Bio-synthesized selenium nanoparticles ameliorate brain oxidative stress in Parkinson disease rat models.Metab. Brain Dis.20233862055206410.1007/s11011‑023‑01222‑6 37133801
     [Google Scholar]
  33. KazemiM. AkbariA. SoleimanpourS. FeiziN. DarroudiM. The role of green reducing agents in gelatin-based synthesis of colloidal selenium nanoparticles and investigation of their antimycobacterial and photocatalytic properties.J. Cluster Sci.201930376777510.1007/s10876‑019‑01537‑4
     [Google Scholar]
  34. ZhangS.Y. ZhangJ. WangH.Y. ChenH.Y. Synthesis of selenium nanoparticles in the presence of polysaccharides.Mater. Lett.200458212590259410.1016/j.matlet.2004.03.031
     [Google Scholar]
  35. VahdatiM. Tohidi MoghadamT. Synthesis and characterization of selenium nanoparticles-lysozyme nanohybrid system with synergistic antibacterial properties.Sci. Rep.202010151010.1038/s41598‑019‑57333‑7 31949299
     [Google Scholar]
  36. Kazemian KakhkiM. MirzaviF. Jalili-NikM. EinafsharE. Nadi YazdiH. SoukhtanlooM. Anticancer effects of beta-cyclodextrin-graphene oxide nanoparticles loaded with selenium on human malignant glioblastoma cells.Bionanoscience20241421075108710.1007/s12668‑024‑01351‑x
     [Google Scholar]
  37. EinafsharE. AslA.H. NiaA.H. MohammadiM. MalekzadehA. RamezaniM. New cyclodextrin-based nanocarriers for drug delivery and phototherapy using an irinotecan metabolite.Carbohydr. Polym.201819410311010.1016/j.carbpol.2018.03.102 29801817
     [Google Scholar]
  38. NaserN.A. MuhammadK. AmeerA. ZahraaK. Solvent effects on the electronic absorption spectra of thymol.Chem. Educ.201520176182
     [Google Scholar]
  39. Shariat RazaviS.A. VafaeiF. EbrahimiS.M. The protective effect of parthenolide in an in vitro model of Parkinson’s disease through its regulation of nuclear factor-kappa B and oxidative stress.Mol. Biol. Rep.202451181910.1007/s11033‑024‑09779‑w 39017801
     [Google Scholar]
  40. KamilogluS. SariG. OzdalT. CapanogluE. Guidelines for cell viability assays.Food Front.20201333234910.1002/fft2.44
     [Google Scholar]
  41. AlaviM.S. FanoudiS. HosseiniA. Jalili-NikM. BagheriA. SadeghniaH.R. Everolimus attenuates glutamate-induced PC12 cells death.Int. J. Neurosci.2023133445746610.1080/00207454.2021.1929210 33998365
     [Google Scholar]
  42. EinafsharE. MobasheriL. HasanpourM. RashidiR. GhorbaniA. Pro-apoptotic effect of chloroform fraction of Moraea sisyrinchium bulb against glioblastoma cells.Biomed. Pharmacother.202417011593110.1016/j.biopha.2023.115931 38016363
     [Google Scholar]
  43. CrowleyL.C. ChojnowskiG. WaterhouseN.J. Measuring the DNA content of cells in apoptosis and at different cell-cycle stages by propidium iodide staining and flow cytometry.Cold Spring Harb. Protoc.201620161010.1101/pdb.prot087247 27698234
     [Google Scholar]
  44. AlaviM.S. Al-AsadyA.M. Abbasinezhad-MoudF. RajabianA. RastegartizabiZ. SadeghniaH.R. Oligoprotective activity of levetiracetam against glutamate toxicity: An in vitro study.Curr. Pharm. Des.2025311576410.2174/0113816128327215240827071257 39279708
     [Google Scholar]
  45. AmiriH. JavidH. EinafsharE. Development and evaluation of PLGA nanoparticles surfaced modified with chitosan-folic acid for improved delivery of resveratrol to prostate cancer cells.Bionanoscience202414298899810.1007/s12668‑024‑01345‑9
     [Google Scholar]
  46. AlaviM.S. NegahS.S. GhorbaniA. HosseiniA. SadeghniaH.R. Levetiracetam promoted rat embryonic neurogenesis via NMDA receptor-mediated mechanism in vitro.Life Sci.202128411992310.1016/j.lfs.2021.119923 34481865
     [Google Scholar]
  47. DinnoA. Nonparametric pairwise multiple comparisons in independent groups using Dunn’s test.Stata J.201515129230010.1177/1536867X1501500117
     [Google Scholar]
  48. ZamaniZ. AlipourD. MoghimiH.R. MortazaviS.A.R. SaffaryM. Development and evaluation of thymol microparticles using cellulose derivatives as controlled release dosage form.Iran. J. Pharm. Res.201514410311040 26664369
     [Google Scholar]
  49. MekkawyA.I. FathyM. MohamedH.B. Evaluation of different surface coating agents for selenium nanoparticles: Enhanced anti-inflammatory activity and drug loading capacity.Drug Des. Devel. Ther.2022161811182510.2147/DDDT.S360344 35719212
     [Google Scholar]
  50. EinafsharE. JavidH. AmiriH. Akbari-ZadehH. HashemyS.I. Curcumin loaded β-cyclodextrin-magnetic graphene oxide nanoparticles decorated with folic acid receptors as a new theranostic agent to improve prostate cancer treatment.Carbohydr. Polym.202434012232810.1016/j.carbpol.2024.122328 38857995
     [Google Scholar]
  51. BishtN. PhalswalP. KhannaP.K. Selenium nanoparticles: A review on synthesis and biomedical applications.Mater. Adv.2022331415143110.1039/D1MA00639H
     [Google Scholar]
  52. AgilanS. VelauthapillaiD. MuthukumarasamyN. ThambiduraiM. SenthilT. BalasundaraprabhuR. Synthesis and characterization of selenium nanowires.Int. Sch. Res. Notices201120113589010.5402/2011/5890
     [Google Scholar]
  53. PouyamaneshG. AmeliN. MetanatY. Thymol enhances] 5-fluorouracil cytotoxicity by reducing migration and increasing apoptosis and cell cycle arrest in esophageal cancer cells: An in-vitro study.Indian J. Clin. Biochem.2024202411210.1007/s12291‑024‑01219‑7
     [Google Scholar]
  54. YuB. ZhangY. ZhengW. FanC. ChenT. Positive surface charge enhances selective cellular uptake and anticancer efficacy of selenium nanoparticles.Inorg. Chem.201251168956896310.1021/ic301050v 22873404
     [Google Scholar]
  55. SrivastavaP. BragancaJ.M. KowshikM. In vivo synthesis of selenium nanoparticles by Halococcus salifodinae BK18 and their anti‐proliferative properties against HeLa cell line.Biotechnol. Prog.20143061480148710.1002/btpr.1992 25219897
     [Google Scholar]
  56. KhuranaA. TekulaS. SaifiM.A. VenkateshP. GoduguC. Therapeutic applications of selenium nanoparticles.Biomed. Pharmacother.201911180281210.1016/j.biopha.2018.12.146 30616079
     [Google Scholar]
  57. SkalickovaS. MilosavljevicV. CihalovaK. HorkyP. RichteraL. AdamV. Selenium nanoparticles as a nutritional supplement.Nutrition201733839010.1016/j.nut.2016.05.001 27356860
     [Google Scholar]
  58. Dong-ChenX. YongC. YangX. Chen-YuS. Li-HuaP. Signaling pathways in Parkinson’s disease: Molecular mechanisms and therapeutic interventions.Signal Transduct. Target. Ther.2023817310.1038/s41392‑023‑01353‑3 36810524
     [Google Scholar]
  59. BernsteinA.I. GarrisonS.P. ZambettiG.P. O’MalleyK.L. 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death.Mol. Neurodegener.201161210.1186/1750‑1326‑6‑2 21211034
     [Google Scholar]
  60. NourmohammadiS. YousefiS. ManouchehrabadiM. FarhadiM. AziziZ. Torkaman-BoutorabiA. Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson’s disease via inhibiting oxidative stress.BMC Complement. Med. Ther.20222214010.1186/s12906‑022‑03524‑1 35144603
     [Google Scholar]
  61. Abu-ElfotuhK. HamdanA.M.E. MohammedA.A. Neuroprotective effects of some nutraceuticals against manganese-induced Parkinson’s disease in rats: Possible modulatory effects on TLR4/NLRP3/NF-κB, GSK-3β, Nrf2/HO-1, and apoptotic pathways.Pharmaceuticals20221512155410.3390/ph15121554 36559006
     [Google Scholar]
  62. MiroliaeeA.E. EsmailyH. Vaziri-BamiA. BaeeriM. ShahverdiA.R. AbdollahiM. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture.Toxicol. Mech. Methods201121320020810.3109/15376516.2010.547887 21247366
     [Google Scholar]
  63. BattinE.E. BrumaghimJ.L. Antioxidant activity of sulfur and selenium: A review of reactive oxygen species scavenging, glutathione peroxidase, and metal-binding antioxidant mechanisms.Cell Biochem. Biophys.200955112310.1007/s12013‑009‑9054‑7 19548119
     [Google Scholar]
  64. JavedH. AzimullahS. MeeranM.F.N. AnsariS.A. OjhaS. Neuroprotective effects of thymol, a dietary monoterpene against dopaminergic neurodegeneration in rotenone-induced rat model of Parkinson’s disease.Int. J. Mol. Sci.2019207153810.3390/ijms20071538 30934738
     [Google Scholar]
  65. HunotS. BruggB. RicardD. Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson disease.Proc. Natl. Acad. Sci. USA199794147531753610.1073/pnas.94.14.7531 9207126
     [Google Scholar]
  66. DengX.Y. LiH.Y. ChenJ.J. Thymol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice.Behav. Brain Res.2015291121910.1016/j.bbr.2015.04.052 25958231
     [Google Scholar]
  67. DaiC. TianE. HaoZ. Aflatoxin B1 toxicity and protective effects of curcumin: Molecular mechanisms and clinical implications.Antioxidants20221110203110.3390/antiox11102031 36290754
     [Google Scholar]
  68. WangQ. ShenZ. QiG. ZhaoY. ZhangH. WangR. Thymol alleviates AGEs-induced podocyte injury by a pleiotropic effect via NF-κB-mediated by RhoA/ROCK signalling pathway.Cell Adhes. Migr.2020141425610.1080/19336918.2020.1721172
     [Google Scholar]
  69. WoodgateA. MacGibbonG. WaltonM. DragunowM. The toxicity of 6-hydroxydopamine on PC12 and P19 cells.Brain Res. Mol. Brain Res.1999691849210.1016/s0169‑328x(99)00103‑5 10350640
     [Google Scholar]
  70. PlescaD. MazumderS. AlmasanA. DNA damage response and apoptosis.Methods Enzymol200844610712210.1016/S0076‑6879(08)01606‑6 18603118
     [Google Scholar]
  71. HanrottK. GudmunsenL. O’NeillM.J. WonnacottS. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta.J. Biol. Chem.200628195373538210.1074/jbc.M511560200 16361258
     [Google Scholar]
  72. MeiJ. NiuC. Effects of CDNF on 6-OHDA-induced apoptosis in PC12 cells via modulation of Bcl-2/Bax and caspase-3 activation.Neurol. Sci.20143581275128010.1007/s10072‑014‑1700‑1 24633814
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128380006250630103711
Loading
Neuroprotective Effects of Thymol-Loaded Selenium Nanoparticles against 6-OHDA-Induced Apoptosis and Oxidative Stress in an In Vitro Parkinson’s Disease Model
Curr. Pharm. Des. 32, 637 (2026); https://doi.org/10.2174/0113816128380006250630103711
/content/journals/cpd/10.2174/0113816128380006250630103711
/content/journals/cpd/10.2174/0113816128380006250630103711
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): 6-hydroxydopamine; monoamine oxidase; oxidative stress; Parkinson's disease; Selenium nanoparticles; thymol

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test